Paula C. Zimbrean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paula C. Zimbrean has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Gerald Scott Winder
Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA
2 shared publicationsMichael L. Schilsky
Digestive Diseases, Transplantation and Immunology, Yale University, New Haven, CT
2 shared publicationsSahil Munjal
Yale University School of Medicine, Department of Psychiatry
2 shared publicationsSukru Emre
Department of Surgery and Pediatrics, Yale University School of Medicine, New Haven, CT
2 shared publicationsThomas Soeprono
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA
2 shared publicationsYanhong Deng
Yale Center for Analytical Sciences, Yale University, New Haven, CT
2 shared publications
Latest Publications
- Open Access
- 19 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5866
Addressing Psychiatric Symptoms in Wilson’s Disease: Translational Overlap with Bipolar Disorder and Emerging Therapeutic Strategies
Background: Wilson’s disease (WD) is a rare autosomal recessive disorder characterized by abnormal copper metabolism and accumulation in the liver and brain. While hepatic and neurological manifestations are well-recognized, psychiatric symptoms remain underdiagnosed and frequently precede other clinical signs, leading to delayed diagnosis and poorer outcomes. Objective: This opinion paper aims to explore the emerging understanding of psychiatric features in WD, particularly mood disturbances and their overlap with bipolar spectrum disorders, through a translational lens. Opinion: Psychiatric manifestations—including irritability, aggression, disinhibition, and mood instability—are observed in up to 100% of symptomatic WD patients. Accumulated copper induces oxidative stress and astrocyte dysfunction, which may disrupt neural circuits involved in emotion regulation. There is increasing evidence of shared pathophysiological mechanisms between WD and bipolar disorder, including redox imbalance and circadian rhythm dysregulation. Future Directions: The timely recognition of psychiatric symptoms is essential. Future research should investigate biomarkers of early psychiatric involvement, evaluate psychotropic medication safety in WD, and implement psychoeducational strategies to improve adherence and quality of life. A translational approach can foster individualized interventions and provide insights into broader mood disorders.
- 19 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5866
Open AccessAddressing Psychiatric Symptoms in Wilson’s Disease: Translational Overlap with Bipolar Disorder and Emerging Therapeutic Strategies
Background: Wilson’s disease (WD) is a rare autosomal recessive disorder characterized by abnormal copper metabolism and accumulation in the liver and brain. While hepatic and neurological manifestations are well-recognized, psychiatric symptoms remain underdiagnosed and frequently precede other clinical signs, leading to delayed diagnosis and poorer outcomes. Objective: This opinion paper aims to explore the emerging understanding of psychiatric features in WD, particularly mood disturbances and their overlap with bipolar spectrum disorders, through a translational lens. Opinion: Psychiatric manifestations—including irritability, aggression, disinhibition, and mood instability—are observed in up to 100% of symptomatic WD patients. Accumulated copper induces oxidative stress and astrocyte dysfunction, which may disrupt neural circuits involved in emotion regulation. There is increasing evidence of shared pathophysiological mechanisms between WD and bipolar disorder, including redox imbalance and circadian rhythm dysregulation. Future Directions: The timely recognition of psychiatric symptoms is essential. Future research should investigate biomarkers of early psychiatric involvement, evaluate psychotropic medication safety in WD, and implement psychoeducational strategies to improve adherence and quality of life. A translational approach can foster individualized interventions and provide insights into broader mood disorders.
- Open Access
- 10 March 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (4) , e1766
Liver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder
Background.: Liver transplantation (LT) is the standard treatment for liver failure secondary to alcohol-associated liver disease, but limited literature and best practices exist for post-LT treatment of alcohol use disorder (AUD). This study explores current AUD management practices and providers’ perceived barriers to effective post-LT AUD management. Methods.: A 45-item survey on post-LT AUD treatment practices was distributed to members of the American Society of Transplant Surgeons, the Association of Consult/Liaison Psychiatry Transplant Special Interest Group, and both the American Society of Transplantation’s Liver and Intestine Community of Practice and Psychosocial and Ethics Community of Practice discussion boards, between December 2021 and April 2022. Univariate analysis of categorical variables was performed using the chi-square test. Data were analyzed using center volume tertiles, country region, and provider professional activity. Results.: Two hundred thirty-two respondents from 70 LT centers across all 11 United Network for Organ Sharing regions completed the survey. Half of the them were attending physicians and 16.4% were nurse coordinators. Most centers (84%) aimed for alcohol abstinence for all post-LT patients. Perceived barriers to AUD treatment efficacy included ongoing desire to drink (18%), denial about alcohol misuse (14.9%), and lack of posttransplant support (14%). Additionally, 62.1% of centers had no policy for prescribing medication-assisted therapy to treat AUD, and 32.7% of centers reported no center-level changes in AUD care. Providers identified primary needs as hiring additional mental health professionals (30.8%), dedicating specific staff to AUD care (24.7%), and standardizing psychiatric/psychological care in transplant clinics (17.2%). Conclusions.: Despite the increasing volume of LT for alcohol-associated liver disease, significant perceived barriers to effective AUD treatment remain.
- 10 March 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (4) , e1766
Open AccessLiver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder
Background.: Liver transplantation (LT) is the standard treatment for liver failure secondary to alcohol-associated liver disease, but limited literature and best practices exist for post-LT treatment of alcohol use disorder (AUD). This study explores current AUD management practices and providers’ perceived barriers to effective post-LT AUD management. Methods.: A 45-item survey on post-LT AUD treatment practices was distributed to members of the American Society of Transplant Surgeons, the Association of Consult/Liaison Psychiatry Transplant Special Interest Group, and both the American Society of Transplantation’s Liver and Intestine Community of Practice and Psychosocial and Ethics Community of Practice discussion boards, between December 2021 and April 2022. Univariate analysis of categorical variables was performed using the chi-square test. Data were analyzed using center volume tertiles, country region, and provider professional activity. Results.: Two hundred thirty-two respondents from 70 LT centers across all 11 United Network for Organ Sharing regions completed the survey. Half of the them were attending physicians and 16.4% were nurse coordinators. Most centers (84%) aimed for alcohol abstinence for all post-LT patients. Perceived barriers to AUD treatment efficacy included ongoing desire to drink (18%), denial about alcohol misuse (14.9%), and lack of posttransplant support (14%). Additionally, 62.1% of centers had no policy for prescribing medication-assisted therapy to treat AUD, and 32.7% of centers reported no center-level changes in AUD care. Providers identified primary needs as hiring additional mental health professionals (30.8%), dedicating specific staff to AUD care (24.7%), and standardizing psychiatric/psychological care in transplant clinics (17.2%). Conclusions.: Despite the increasing volume of LT for alcohol-associated liver disease, significant perceived barriers to effective AUD treatment remain.
- Open Access
- 11 December 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (1)
Depression and anxiety management in cirrhosis
Depressive and anxiety symptoms are more prevalent in patients with cirrhosis compared to the general population. Between 2009 and 2019, the prevalence of depression in cirrhosis increased by 80%, while the prevalence of generalized anxiety disorder increased by over 400%. When present, anxiety and depression are linked to lower health-related quality of life, more severe symptoms (eg, fatigue), and poorer response to medical treatment. Screening instruments for depression and anxiety have shown acceptable validity in patients with cirrhosis. However, the diagnosis of depression and anxiety disorder remains challenging in this population and should follow the established criteria for general populations. Treatment interventions are numerous and include patient education and support around liver disease, pharmacological agents, and psychotherapy. Antidepressants are the treatment of choice for patients with depressive or anxiety disorder and cirrhosis. However, consideration must be given to dose adjustment and choice of agent due to changes in their metabolism in patients with liver disease. Psychotherapy may be used as a stand-alone therapy or concomitantly with pharmacotherapy. The high prevalence and complexity of depressive and anxiety symptoms in patients with cirrhosis support the integrated care approach in which patients are cared for by multidisciplinary teams.
- 11 December 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (1)
Open AccessDepression and anxiety management in cirrhosis
Depressive and anxiety symptoms are more prevalent in patients with cirrhosis compared to the general population. Between 2009 and 2019, the prevalence of depression in cirrhosis increased by 80%, while the prevalence of generalized anxiety disorder increased by over 400%. When present, anxiety and depression are linked to lower health-related quality of life, more severe symptoms (eg, fatigue), and poorer response to medical treatment. Screening instruments for depression and anxiety have shown acceptable validity in patients with cirrhosis. However, the diagnosis of depression and anxiety disorder remains challenging in this population and should follow the established criteria for general populations. Treatment interventions are numerous and include patient education and support around liver disease, pharmacological agents, and psychotherapy. Antidepressants are the treatment of choice for patients with depressive or anxiety disorder and cirrhosis. However, consideration must be given to dose adjustment and choice of agent due to changes in their metabolism in patients with liver disease. Psychotherapy may be used as a stand-alone therapy or concomitantly with pharmacotherapy. The high prevalence and complexity of depressive and anxiety symptoms in patients with cirrhosis support the integrated care approach in which patients are cared for by multidisciplinary teams.
- 24 April 2024
- Published by Springer Nature in Current Transplantation Reports
- Vol. 11 (2) , 63-76
Psychometric Analysis for a Standardized Approach When Evaluating Liver Transplant Candidates with Acute Alcohol-Related Hepatitis
- 24 April 2024
- Published by Springer Nature in Current Transplantation Reports
- Vol. 11 (2) , 63-76
Psychometric Analysis for a Standardized Approach When Evaluating Liver Transplant Candidates with Acute Alcohol-Related Hepatitis
- 23 October 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (5) , 505-518
Psychosocial evaluation of living liver donors—State of current practices in the United States
We surveyed living donor liver transplant programs in the United States to describe practices in the psychosocial evaluation of living donors focused on (1) composition of psychosocial team; (2) domains, workflow, and tools of the psychosocial assessment; (3) absolute and relative mental health-related contraindications to donation; and (4) postdonation psychosocial follow-up. We received 52 unique responses, representing 33 of 50 (66%) of active living donor liver transplant programs. Thirty-one (93.9%) provider teams included social workers, 22 (66.7%) psychiatrists, and 14 (42.4%) psychologists. Validated tools were rarely used, but domains assessed were consistent. Respondents rated active alcohol (93.8%), cocaine (96.8%), and opioid (96.8%) use disorder, as absolute contraindications to donation. Active suicidality (97%), self-injurious behavior (90.9%), eating disorders (87.9%), psychosis (84.8%), nonadherence (71.9%), and inability to cooperate with the evaluation team (78.1%) were absolute contraindications to donation. There were no statistically significant differences in absolute psychosocial contraindications to liver donation between geographical areas or between large and small programs. Programs conduct postdonation psychosocial follow-up (57.6%) or screening (39.4%), but routine follow-up of declined donors is rarely conducted (15.8%). Psychosocial evaluation of donor candidates is a multidisciplinary process. The structure of the psychosocial evaluation of donors is not uniform among programs though the domains assessed are consistent. Psychosocial contraindications to living liver donation vary among the transplant programs. Mental health follow-up of donor candidates is not standardized.
- 23 October 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 30 (5) , 505-518
Psychosocial evaluation of living liver donors—State of current practices in the United States
We surveyed living donor liver transplant programs in the United States to describe practices in the psychosocial evaluation of living donors focused on (1) composition of psychosocial team; (2) domains, workflow, and tools of the psychosocial assessment; (3) absolute and relative mental health-related contraindications to donation; and (4) postdonation psychosocial follow-up. We received 52 unique responses, representing 33 of 50 (66%) of active living donor liver transplant programs. Thirty-one (93.9%) provider teams included social workers, 22 (66.7%) psychiatrists, and 14 (42.4%) psychologists. Validated tools were rarely used, but domains assessed were consistent. Respondents rated active alcohol (93.8%), cocaine (96.8%), and opioid (96.8%) use disorder, as absolute contraindications to donation. Active suicidality (97%), self-injurious behavior (90.9%), eating disorders (87.9%), psychosis (84.8%), nonadherence (71.9%), and inability to cooperate with the evaluation team (78.1%) were absolute contraindications to donation. There were no statistically significant differences in absolute psychosocial contraindications to liver donation between geographical areas or between large and small programs. Programs conduct postdonation psychosocial follow-up (57.6%) or screening (39.4%), but routine follow-up of declined donors is rarely conducted (15.8%). Psychosocial evaluation of donor candidates is a multidisciplinary process. The structure of the psychosocial evaluation of donors is not uniform among programs though the domains assessed are consistent. Psychosocial contraindications to living liver donation vary among the transplant programs. Mental health follow-up of donor candidates is not standardized.
- 30 March 2023
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 64 (4) , 357-370
ACLP Best Practice Guidance: Evaluation and Treatment of Depression in Solid Organ Transplant Recipients
- 30 March 2023
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 64 (4) , 357-370
ACLP Best Practice Guidance: Evaluation and Treatment of Depression in Solid Organ Transplant Recipients
- 12 December 2022
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 64 (2) , 106-117
Major Depressive Disorder in an International Multisite Wilson Disease Registry
- 12 December 2022
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 64 (2) , 106-117
Major Depressive Disorder in an International Multisite Wilson Disease Registry
- 13 October 2022
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 27 (6) , 535-545
Depression in transplantation
Purpose of review: To review and summarize the literature published between 1 January 2020 and 30 June 2022, on the prevalence, risk factors and impact of depression in transplant population. Recent findings: Depression is common in transplantation candidates and recipients, with a prevalence up to 85.8% in kidney recipients. Multiple studies have indicated after transplantation depression correlates with increased mortality and with higher healthcare utilization. Social risk factors for posttransplant depression include financial difficulties and unemployment, while less is understood about the biological substrate of depression in this population. There is evidence that dynamic psychotherapy is effective for depression in organ transplant recipients, while cognitive behavioral therapy or supportive therapy did not lead to improvement of depression in transplant recipients. For living organ donors, the rates of depression are similar to the general population, with financial factors and the clinical status of the recipient playing a significant role. Summary: Depression is a common finding in transplant population. More research is needed to understand the biological substrate and risk factors and to develop effective treatment interventions.
- 13 October 2022
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 27 (6) , 535-545
Depression in transplantation
Purpose of review: To review and summarize the literature published between 1 January 2020 and 30 June 2022, on the prevalence, risk factors and impact of depression in transplant population. Recent findings: Depression is common in transplantation candidates and recipients, with a prevalence up to 85.8% in kidney recipients. Multiple studies have indicated after transplantation depression correlates with increased mortality and with higher healthcare utilization. Social risk factors for posttransplant depression include financial difficulties and unemployment, while less is understood about the biological substrate of depression in this population. There is evidence that dynamic psychotherapy is effective for depression in organ transplant recipients, while cognitive behavioral therapy or supportive therapy did not lead to improvement of depression in transplant recipients. For living organ donors, the rates of depression are similar to the general population, with financial factors and the clinical status of the recipient playing a significant role. Summary: Depression is a common finding in transplant population. More research is needed to understand the biological substrate and risk factors and to develop effective treatment interventions.
- 1 January 2022
- Published by Springer Nature
- p. 183-188
Gambling Disorders in Organ Transplant Recipients
- 1 January 2022
- Published by Springer Nature
- p. 183-188
Gambling Disorders in Organ Transplant Recipients
- 1 January 2022
- Published by Springer Nature
- p. 199-204
The Multiple Roles of the Transplant Psychiatrist
- 1 January 2022
- Published by Springer Nature
- p. 199-204
The Multiple Roles of the Transplant Psychiatrist